High expression of CIP2A contributes to imatinib resistance in CML and is a strong prospective predictor of subsequent development of BC in imatinib-treated patients.5 However the mechanism(s) by which CIP2A increases the risk of disease progression is poorly understood. Here, CIP2A is linked to breast cancer.